Noursadeghi E, Jafari A, Saghiri R, Sauve R, Eliassi A
Neurophysiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neuromolecular Med. 2014 Dec;16(4):862-71. doi: 10.1007/s12017-014-8334-6. Epub 2014 Oct 26.
Existing evidence indicates an impairment of mitochondrial functions and alterations in potassium channel activities in diabetes. Because mitochondrial potassium channels have been involved in several mitochondrial functions including cytoprotection, apoptosis and calcium homeostasis, a study was carried out to consider whether the gating behavior of the mitochondrial ATP- and ChTx-insensitive Ca(2+)-activated potassium channel (mitoBKCa) is altered in a streptozotocin (STZ) model of diabetes. Using ion channel incorporation of brain mitochondrial inner membrane into the bilayer lipid membrane, we provide in this work evidence for modifications of the mitoBKCa ion permeation properties with channels from vesicles preparations coming from diabetic rats characterized by a significant decrease in conductance. More importantly, the open probability of channels from diabetic rats was reduced 1.5-2.5 fold compared to control, the most significant decrease being observed at depolarizing potentials. Because BKCa β4 subunit has been documented to left shift the BKCa channel voltage dependence curve in high Ca(2+) conditions, a Western blot analysis was undertaken where the expression of mitoBKCa α and β4 subunits was estimated using of anti-α and β4 subunit antibodies. Our results indicated a significant decrease in mitoBKCa β4 subunit expression coupled to a decrease in the expression of α subunit, an observation compatible with the observed decrease in Ca(2+) sensitivity. Our results thus demonstrate a modification in the mitoBKCa channel gating properties in membrane preparations coming from STZ model of diabetic rats, an effect potentially linked to a change in mitoBKCa β4 and α subunits expression and/or to an increase in reactive oxygen species production in high glucose conditions.
现有证据表明,糖尿病患者存在线粒体功能受损以及钾通道活性改变的情况。由于线粒体钾通道参与了包括细胞保护、细胞凋亡和钙稳态在内的多种线粒体功能,因此开展了一项研究,以探讨在链脲佐菌素(STZ)诱导的糖尿病模型中,线粒体ATP和ChTx不敏感的钙激活钾通道(mitoBKCa)的门控行为是否发生改变。通过将脑线粒体内膜的离子通道整合到双层脂质膜中,我们在这项研究中发现,来自糖尿病大鼠囊泡制剂的mitoBKCa离子渗透特性发生了改变,其特征是电导显著降低。更重要的是,与对照组相比,糖尿病大鼠通道的开放概率降低了1.5至2.5倍,在去极化电位下观察到最显著的降低。由于BKCaβ4亚基已被证明在高钙条件下会使BKCa通道电压依赖性曲线向左移动,因此进行了蛋白质免疫印迹分析,使用抗α和β4亚基抗体估计mitoBKCaα和β4亚基的表达。我们的结果表明,mitoBKCaβ4亚基表达显著降低,同时α亚基表达也降低,这一观察结果与所观察到的钙敏感性降低相一致。因此,我们的结果证明了来自糖尿病大鼠STZ模型的膜制剂中mitoBKCa通道门控特性发生了改变,这种效应可能与mitoBKCaβ4和α亚基表达的变化以及高糖条件下活性氧生成增加有关。